

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM399969

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
JPMorgan Chase Bank, N.A., as Administrative Agent		09/28/2016	national association: UNITED STATES
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Medivation, Inc.		
<b>Street Address:</b>	525 MARKET STREET		
<b>Internal Address:</b>	36TH FLOOR		
<b>City:</b>	SAN FRANCISCO		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94105		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4949163	MEDIVATION	
<b>Registration Number:</b>	4939113	MEDIVATION	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	3129939767		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	3129932647		
<b>Email:</b>	zeynep.gieseke@lw.com		
<b>Correspondent Name:</b>	Zeynep Gieseke		
<b>Address Line 1:</b>	330 N. Wabash Avenue, Suite 2800		
<b>Address Line 2:</b>	Latham & Watkins LLP		
<b>Address Line 4:</b>	Chicago, ILLINOIS 60611		
<b>ATTORNEY DOCKET NUMBER:</b>	049067-0104		
<b>NAME OF SUBMITTER:</b>	Zeynep Gieseke		
<b>SIGNATURE:</b>	/zg/		
<b>DATE SIGNED:</b>	09/28/2016		
<b>Total Attachments: 15</b>			
source=Intellectual Property Release#page1.tif			

CH \$65.00 4949163

source=Intellectual Property Release#page2.tif  
source=Intellectual Property Release#page3.tif  
source=Intellectual Property Release#page4.tif  
source=Intellectual Property Release#page5.tif  
source=Intellectual Property Release#page6.tif  
source=Intellectual Property Release#page7.tif  
source=Intellectual Property Release#page8.tif  
source=Intellectual Property Release#page9.tif  
source=Intellectual Property Release#page10.tif  
source=Intellectual Property Release#page11.tif  
source=Intellectual Property Release#page12.tif  
source=Intellectual Property Release#page13.tif  
source=Intellectual Property Release#page14.tif  
source=Intellectual Property Release#page15.tif

**RELEASE OF SECURITY INTEREST  
IN INTELLECTUAL PROPERTY COLLATERAL**

This **RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL** (this "Release"), dated as of September 28, 2016, is made by **JPMORGAN CHASE BANK, N.A.**, as Administrative Agent (the "Administrative Agent"), under the Credit Agreement referred to below (terms used in this Release and not herein defined shall have the meanings set forth in the Credit Agreement).

**WHEREAS**, in connection with that certain Amended and Restated Credit Agreement dated as of October 23, 2015 (as amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement"), among Medivation, Inc., a Delaware corporation (the "Borrower"), the Lenders party thereto and Administrative Agent, the Lenders have agreed to make loans and extend other financial accommodations to or for the benefit of the Borrower;

**WHEREAS**, the Borrower and the other Loan Parties have entered into an Amended and Restated Pledge and Security Agreement dated as of October 23, 2015 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement");

**WHEREAS**, in connection with the Credit Agreement, Security Agreement and pursuant to those certain agreements described on Annex I attached hereto (collectively, the "IP Security Agreements"), the Borrower and certain other Loan Parties granted security interests in the certain intellectual property owned by Borrower and the other Loan Parties, including those listed on Annex I attached hereto (the "IP Collateral"); and

**WHEREAS**, the IP Security Agreements were recorded in the U.S. Patent and Trademark Office on the dates and on the reels and frames set forth on Annex I hereto.

**NOW THEREFORE**, in consideration of the material covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent hereby **RELEASES**, terminates and discharges, without representation, recourse or warranty whatsoever, all of its rights in, to and under, including its Lien on and security interest in, and right of setoff against, the IP Collateral, whether granted pursuant to the Security Agreement, the IP Security Agreements or any other agreement or document delivered in connection with the Credit Agreement, and the Administrative Agent hereby reassigns any and all such right, title and interest (if any) that the Administrative Agent may have in, to and under the IP Collateral to Borrower.


The Administrative Agent agrees, at Borrower's expense, to cooperate with Borrower and to provide Borrower with the information and additional authorization reasonably required or desirable to effect the release of the Administrative Agent's security interest in the released collateral described herein.

This Release and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York.

[Signature Page Follows]

**IN WITNESS WHEREOF**, the Administrative Agent has executed this Release as of the date first above written.

**JPMORGAN CHASE BANK, N.A.,**  
as Administrative Agent

By:   
Name: Alex Rogin  
Title: Executive Director

**ANNEX I**

Confirmatory Grant of Security Interest in United States Patents dated as of September 4, 2015, by Medivation Neurology, Inc. in favor of Administrative Agent, was recorded with the U.S. Patent and Trademark Office on September 4, 2015 at Reel/Frame No. 036553/0899.

<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Application Date</b>	<b>Patent Number</b>	<b>Status</b>	<b>Grantor</b>
AGENT FOR TREATING NEURODEGENERATIVE DISORDERS	United States	9269602	3/25/1999	6187785	Issued	Medivation Neurology, Inc.

Confirmatory Grant of Security Interest in United States Patents dated as of September 4, 2015, by Medivation Prostate Therapeutics, Inc. and Medivation Technologies, Inc. in favor of Administrative Agent, was recorded with the U.S. Patent and Trademark Office on September 4, 2015 at Reel/Frame No. 036553/0912 and Reel/Frame No. 036553/0925.

Title	Country	Application Number	Application Date	Patent Number	Status	Grantor
METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA USING ATYPICAL ANTIPSYCHOTIC THERAPY	United States	12/671,679	08/01/2008		Filed	Medivation Technologies, Inc.
TETRACYCLIC COMPOUNDS	United States	13/725,909	12/21/2012	9,181,240	Granted	Medivation Technologies, Inc.
NEW TETRACYCLIC COMPOUNDS	United States	13/797,723	03/12/2013	9,096,591	Allowed	Medivation Technologies, Inc.
NEW TETRACYCLIC COMPOUNDS	United States	14/631,615	02/25/2015		Filed	Medivation Technologies, Inc.
TETRACYCLIC COMPOUNDS	United States	12/259,234	10/27/2008	8,338,408	Granted	Medivation Technologies, Inc.
TETRACYCLIC COMPOUNDS	United States	13/679,873	11/16/2012	8999978	Granted	Medivation Technologies, Inc.
TETRACYCLIC COMPOUNDS	United States	13/791,750	03/08/2013	9034880	Granted	Medivation Technologies, Inc.
NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF	United States	13/789,604	03/07/2013		Filed	Medivation Technologies, Inc.
NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF	United States	13/791,835	03/08/2013		Filed	Medivation Technologies, Inc.
NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF	United States	12/360,061	01/26/2009	9115137	Granted	Medivation Technologies, Inc.

TRADEMARK

REEL: 005885 FRAME: 0686

TRADEMARK

BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE	United States	12/410,425	03/24/2009	8,546,381	Granted	Medivation Technologies, Inc.
BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE	United States	13/789,606	03/07/2013	9034869	Granted	Medivation Technologies, Inc.
BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE	United States	13/791,832	03/08/2013	8999977	Granted	Medivation Technologies, Inc.
BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE	United States	14/033,234	09/20/2013	9051314	Granted	Medivation Technologies, Inc.
PYRIDO[3,4-B]INDOLES AND METHODS OF USE	United States	13/679,883	11/16/2012		Filed	Medivation Technologies, Inc.
PYRIDO[3,4-B]INDOLES AND METHODS OF USE	United States	13/725,937	12/21/2012	9,260,429	Granted	Medivation Technologies, Inc.
PYRIDO[3,4-B]INDOLES AND METHODS OF USE	United States	13/791,677	12/21/2012		Filed	Medivation Technologies, Inc.
PYRIDO[3,4-B]INDOLES AND METHODS OF USE	United States	13/791,781	03/08/2013		Filed	Medivation Technologies, Inc.
PYRIDO[3,4-B]INDOLES AND METHODS OF USE	United States	14/410,407	03/24/2009	8,338,447	Granted	Medivation Technologies, Inc.
PYRIDO(4,3-B)INDOLES CONTAINING RIGID MOIETIES	United States	14/531,915	11/03/2014		Filed	Medivation Technologies, Inc.
PYRIDO(4,3-B)INDOLES CONTAINING RIGID MOIETIES	United States	12/610,217	10/30/2009	8,907,097	Granted	Medivation Technologies, Inc.
PYRIDO(4,3-B)INDOLES CONTAINING RIGID MOIETIES	United States	13/791,544	03/08/2013	8,906,925	Granted	Medivation Technologies, Inc.

REEL: 005885 FRAME: 0687

TRADEMARK

AZEPIINO[4,5-B]INDOLES AND METHODS OF USE	United States	13/791,867	03/08/2013		Filed	Medivation Technologies, Inc.
AZEPIINO[4,5-B]INDOLES AND METHODS OF USE	United States	13/791,648	03/08/2013	9,409,910	Granted	Medivation Technologies, Inc.
AZEPIINO[4,5-B]INDOLES AND METHODS OF USE	United States	14/048,656	10/08/2013		Filed	Medivation Technologies, Inc.
AZEPIINO[4,5-B]INDOLES AND METHODS OF USE	United States	12/610,152	10/30/2009	8,569,287	Granted	Medivation Technologies, Inc.
SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS	United States	13/925,507	06/24/2013	9,023,879	Granted	Medivation Prostate Therapeutics, Inc.
SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS	United States	13/202,970	10/27/2011	8,524,755	Granted	Medivation Prostate Therapeutics, Inc.
SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTION COMPOUNDS AND METHODS OF USE THEREOF	United States	13/263,728	12/05/2011	8,710,086	Granted	Medivation Technologies, Inc.
SUBSTITUTED PHENYL-CARBAMOYL ALKYLAMINO ARENE COMPOUNDS AND METHOD OF USE THEREOF	United States	13/685,013	11/26/2012	9,023,869	Granted	Medivation Technologies, Inc.
SUBSTITUTED PHENYL-CARBAMOYL ALKYLAMINO ARENE COMPOUNDS AND METHOD OF USE THEREOF	United States	14/514,974	10/15/2014	9,126,962	Granted	Medivation Technologies, Inc.
PYRIDO[3,4-B]INDOLES AND METHODS OF USE	United States	13/318,123	02/08/2012	9,255,094	Granted	Medivation Technologies, Inc.
PYRIDO[3,4-B]INDOLES AND METHODS OF USE	United States	13/791,796	03/08/2013		Filed	Medivation Technologies, Inc.

REEL: 005885 FRAME: 0688



TRADEMARK

PYRIDO[3,4-B]INDOLES AND METHODS OF USE	United States	13/791,862	03/08/2013	8,927,571	Granted	Medivation Technologies, Inc.
PYRIDO[3,4-B]INDOLES AND METHODS OF USE	United States	13/318,124	01/10/2012	8,741,919	Granted	Medivation Technologies, Inc.
PYRIDO[3,4-B]INDOLES AND METHODS OF USE	United States	14/738,465	06/12/2015	9,271,971	Granted	Medivation Technologies, Inc.
PYRIDO[3,4-B]INDOLES AND METHODS OF USE	United States	12/889,323	09/23/2010	9,079,904	Granted	Medivation Technologies, Inc.
PYRIDO[3,4-B]INDOLES AND METHODS OF USE	United States	13/791,559	03/08/2013	9,085,580	Granted	Medivation Technologies, Inc.
PYRIDO[4,3-B]INDOLES AND METHODS OF USE	United States	13/791,874	03/08/2013	9,199,996	Granted	Medivation Technologies, Inc.
PYRIDO[4,3-B]INDOLES AND METHODS OF USE	United States	14/485,238	09/12/2014		Filed	Medivation Technologies, Inc.
PYRIDO[4,3-B]INDOLES AND METHODS OF USE	United States	12/889,338	09/23/2010	8,859,561	Granted	Medivation Technologies, Inc.
PYRIDO[4,3-B]INDOLES AND METHODS OF USE	United States	13/791,871	03/08/2013	9,045,482	Granted	Medivation Technologies, Inc.
PROCESS FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS	United States	13/785,504	03/05/2013	9,174,943	Granted	Medivation Prostate Therapeutics, Inc.
PYRIDO[3,4-B]INDOLES AND METHODS OF USE	United States	13/498,099	09/23/2010		Filed	Medivation Technologies, Inc.
PYRIDO[3,4-B]INDOLES AND METHODS OF USE	United States	13/734,873	01/04/2013		Filed	Medivation Technologies, Inc.

								Inc.
BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE	United States	13/540472	07/02/2012	9,006,234	Allowed	Medivation Technologies, Inc.		
FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE	United States	13/579,900	02/18/2011	9,193,728	Granted	Medivation Technologies, Inc.		
PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE	United States	14/701,244	04/30/2015	9,433,626	Granted	Medivation Technologies, Inc.		
PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE	United States	13/579,904	03/04/2013	9,034,865	Granted	Medivation Technologies, Inc.		
PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE	United States	13/579,908	02/18/2011	9,187,471	Granted	Medivation Technologies, Inc.		
FUSED TETRACYCLIC PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE	United States	13/579,911	03/04/2013	9,040,519	Granted	Medivation Technologies, Inc.		
PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE	United States	13/579,912	02/18/2011		Filed	Medivation Technologies, Inc.		
PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE	United States	14/666,101	03/23/2015	9,211,287	Granted	Medivation Technologies, Inc.		
PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE	United States	14/000,179	11/26/2013	9,035,056	Granted	Medivation Technologies, Inc.		
COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION	United States	14/000,171	11/27/2013	9,199,985	Granted	Medivation Technologies, Inc.		
COMPOUNDS AND METHODS OF TREATING DIABETES	United States	14/000,176	11/26/2013		Filed	Medivation Technologies, Inc.		

TRADEMARK

TRADEMARK

COMPOUNDS AND METHODS OF TREATING HYPERTENSION	United States	14/000,184	11/27/2013		Filed	Medivation Technologies, Inc.
COMPOUNDS AND METHODS OF TREATING DIABETES	United States	14/000,197	11/22/2013	9,434,747	Granted	Medivation Technologies, Inc.
COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION	United States	14/641,232	03/06/2015		Filed	Medivation Technologies, Inc.
COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION	United States	13/400,031	02/17/2012	8,791,132	Granted	Medivation Technologies, Inc.
COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION	United States	13/789,361	03/07/2013	9,006,263	Granted	Medivation Technologies, Inc.
COMPOUNDS AND METHODS OF TREATING DIABETES	United States	13/400,032	02/17/2012	8,815,843	Granted	Medivation Technologies, Inc.
COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION	United States	14/423,027	03/15/2013		Filed	Medivation Technologies, Inc.
FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF	United States	14/141,003	12/26/2013	9,422,267	Granted	Medivation Technologies, Inc.
FORMULATIONS OF ENZALUTAMIDE	United States	14/023,878	09/11/2013		Filed	Medivation Prostate Therapeutics, Inc.
FORMULATIONS OF ENZALUTAMIDE	United States	14/481,986	09/10/2014		Filed	Medivation Prostate Therapeutics, Inc.
TREATMENT OF BREAST CANCER	United States	14/236,036	06/10/2014		Filed	Medivation Prostate Therapeutics, Inc.

TRADEMARK


HETEROCYCLIC COMPOUNDS AND METHODS OF USE	United States	14/471,977	08/28/2014		Filed	Medivation Technologies, Inc.
AMORPHOUS DRUG FORMULATIONS	United States	14/538,963	11/12/2014		Filed	Medivation Technologies, Inc.
FUSED CYCLOALKYL-PYRIMIDINE COMPOUNDS AND USES THEREOF	United States	62/020,303	07/02/2014		Filed	Medivation Technologies, Inc.
COMPOUNDS AND METHODS OF USE	United States	62/075,546	11/05/2014		Filed	Medivation Technologies, Inc.
HETEROCYCLIC COMPOUNDS AND METHODS OF USE	United States	62/128,251	03/04/2015		Filed	Medivation Technologies, Inc.
METHODS OF PREDICTING RESPONSE TO BREAST CANCER THERAPEUTIC AGENTS	United States	62/091,195	12/12/2014		Filed	Medivation Prostate Therapeutics, Inc.
METHODS OF PREDICTING RESPONSE TO BREAST CANCER THERAPEUTIC AGENTS	United States	62/142,504	04/03/2015		Filed	Medivation Prostate Therapeutics, Inc.
METHODS AND COMPOSITIONS FOR TARGETED THERAPEUTICS	United States	62/198,616	07/29/2015		Filed	Medivation Technologies, Inc.
METHODS AND COMPOSITIONS FOR TARGETED THERAPEUTICS	United States	62/198,604	07/29/2015		Filed	Medivation Technologies, Inc.
METHODS AND COMPOSITIONS FOR TARGETED THERAPEUTICS	United States	62/198,609	07/29/2015		Filed	Medivation Technologies, Inc.
COMPOSITIONS AND METHODS	United States	62/198,555	07/29/2015		Filed	Medivation Technologies, Inc.

COMPOSITIONS AND METHODS	United States	62/198,592	07/29/2015		Filed	Medivation Technologies, Inc.
COMBINATION THERAPY	United States	62/204,281	08/12/2015		Filed	Medivation Prostate Therapeutics, Inc.
COMBINATION THERAPY	United States	62/204,287	08/12/2015		Filed	Medivation Technologies, Inc.
COMBINATION THERAPY	United States	62/204,954	08/13/2015		Filed	Medivation Prostate Therapeutics, Inc.
COMPOUNDS AND METHODS FOR TREATING DIABETES	United States	13/789376	03/07/2013		Filed	Medivation Technologies, Inc.

**TRADEMARK**

**REEL: 005885 FRAME: 0693**

Confirmatory Grant of Security Interest in United States Trademarks dated as of September 4, 2015, by Medivation, Inc., a Delaware corporation, in favor of Administrative Agent, was recorded with the U.S. Patent and Trademark Office on September 4, 2015 at Reel/Frame No. 5617/0599.

<b>Trademark</b>	<b>App. No. App. Date</b>	<b>Reg. No. Reg. Date</b>	<b>Status</b>	<b>Owner</b>
	86539986 2/19/2015	4949163 5/3/2016	Registered	Medivation, Inc.
MEDIVATION	86538885 2/18/2015	4939113 4/19/2016	Registered	Medivation, Inc.

Confirmatory Grant of Security Interest in United States Patents dated as of October 23, 2015, by Medivation, Inc., in favor of Administrative Agent, was recorded with the U.S. Patent and Trademark Office on October 23, 2015 at Reel/Frame No. 036866/0635.

Title	Country	Application Number	Application Date	Patent Number	Status
DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)	United States	61/086,687	8/6/2008		Filed
DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)	United States	61/151,036	2/9/2009		Filed
DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)	United States	61/173,088	4/27/2009		Filed
DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)	United States	61/325,126	4/16/2010		Filed
DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)	United States	12/510,096	7/27/2009	8,012,976	Issued
DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)	United States	13/077,785	3/31/2011	8,420,650	Issued
DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)	United States	13/787,496	3/6/2013	8,999,987	Issued
DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)	United States	14/632,825	2/26/2015		Filed
DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)	United States	61/301,174	2/3/2010		Filed

DHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY	United States	13/020,619	2/3/2011	8,541,403	Issued
DHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY	United States	13/972,166	8/21/2013	9,018,201	Issued
DHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY	United States	14/671,944	3/27/2015		Filed
PROCESSES OF SYNTHESIZING DIHYDROPYRIDOPHTHALAZINONE DERIVATIVES	United States	61/302,457	2/8/2010		Filed
PROCESSES OF SYNTHESIZING DIHYDROPYRIDOPHTHALAZINONE DERIVATIVES	United States	13/023,140	2/8/2011	8,765,945	Issued
PROCESSES OF SYNTHESIZING DIHYDROPYRIDOPHTHALAZINONE DERIVATIVES	United States	14/293,642	6/2/2014		Filed
CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-	United States	61/405,476	10/21/2010		Filed
2H-PYRIDO [4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT					
CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-	United States	13/277,607	10/20/2011	8,735,392	Issued
2H-PYRIDO [4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT					
CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-	United States	14/252,668	4/14/2014		Filed
2H-PYRIDO [4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT					



TRIAZOLE INTERMEDIATES USEFUL IN THE SYNTHESIS OF PROTECTED N-ALKYL TRIAZOLE CARBALDEHYDES	United States	61/901,300	11/7/2013		Filed
COFORMER SALTS OF (2S,3S)-METHYL 7-FLUORO-2-(4-FLUOROPHENYL)-3-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-4-OXO-1,2,3,4-TETRAHYDROQUINOLINE-5-CARBOXYLATE AND METHODS OF PREPARING THEM	United States	62/031,521	7/31/2014		Filed
PRODRUGS OF PARP INHIBITORS	United States	62/156,772	5/4/2015		Filed
PRODRUGS OF PARP INHIBITORS	United States	61/987,344	5/1/2014		Filed

TRADEMARK  
REEL: 005885 FRAME: 0697

RECORDED: 09/28/2016